Literature DB >> 17786047

Replicational stress selects for p53 mutation.

Andriy Marusyk1, James DeGregori.   

Abstract

p53 is a critical mediator of cellular responses to a variety of stresses. Given the frequency of p53 mutations in human malignancies and that disruption of p53 has been implicated in chemoresistance, understanding the factors that select for p53 disruption is important both for understanding tumor evolution and for designing cancer therapies. While it is widely believed that genotoxic stress selects for p53 mutations, the effects of DNA damaging agents on long-term proliferative potential are usually not affected by p53 status. Previous reports have demonstrated that despite being activated, p53 loss does not prevent cell cycle arrest and senescence in response to high levels of acute replicational stress. In contrast, we recently reported that chronic exposure of non-transformed cells to low, clinically relevant levels of replicational stress induces p53-dependent senescence-like arrest. Disruption of p53 or its target gene p21(CIP1) antagonizes this arrest, leading to a long-term proliferative advantage. However, when replicational stress is associated with substantial DNA strand breaks, the ability of p53 disruption to up-regulate RAD51 dependent homologous recombination becomes important. Replicational stress is induced by many chemotherapeutic treatments and perhaps by some dietary deficiencies, and may be an important factor that selects for p53 mutations during cancer initiation and progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786047      PMCID: PMC2394679          DOI: 10.4161/cc.6.17.4732

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  32 in total

1.  p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination.

Authors:  Steven P Linke; Sagar Sengupta; Nissim Khabie; Beth A Jeffries; Sabine Buchhop; Stefan Miska; Wilhelm Henning; Remy Pedeux; Xin W Wang; Lorne J Hofseth; Qin Yang; Susan H Garfield; Horst-Werner Stürzbecher; Curtis C Harris
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

2.  p53 protects from replication-associated DNA double-strand breaks in mammalian cells.

Authors:  Anuradha Kumari; Niklas Schultz; Thomas Helleday
Journal:  Oncogene       Date:  2004-03-25       Impact factor: 9.867

Review 3.  Molecular anatomy of the DNA damage and replication checkpoints.

Authors:  Jun Qin; Lei Li
Journal:  Radiat Res       Date:  2003-02       Impact factor: 2.841

4.  ATR activation necessary but not sufficient for p53 induction and apoptosis in hydroxyurea-hypersensitive myeloid leukemia cells.

Authors:  Sujatha Kumar; Gerald E Dodson; Anthony Trinh; Joel R Puchalski; Randal S Tibbetts
Journal:  Cell Cycle       Date:  2005-11-13       Impact factor: 4.534

5.  Savior and slayer: the two faces of p53.

Authors:  Karim Bensaad; Karen H Vousden
Journal:  Nat Med       Date:  2005-12       Impact factor: 53.440

6.  Double bolt regulation of Rad51 by p53: a role for transcriptional repression.

Authors:  Iciar Lazaro-Trueba; Carmen Arias; Augusto Silva
Journal:  Cell Cycle       Date:  2006-05-15       Impact factor: 4.534

Review 7.  Carcinogenesis, cancer therapy and chemoprevention.

Authors:  M V Blagosklonny
Journal:  Cell Death Differ       Date:  2005-06       Impact factor: 15.828

8.  Impaired DNA replication within progenitor cell pools promotes leukemogenesis.

Authors:  Ganna Bilousova; Andriy Marusyk; Christopher C Porter; Robert D Cardiff; James DeGregori
Journal:  PLoS Biol       Date:  2005-11-15       Impact factor: 8.029

9.  Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment.

Authors:  Alexander R A Anderson; Alissa M Weaver; Peter T Cummings; Vito Quaranta
Journal:  Cell       Date:  2006-12-01       Impact factor: 41.582

10.  p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene.

Authors:  Carmen Arias-Lopez; Iciar Lazaro-Trueba; Peter Kerr; Christopher J Lord; Tim Dexter; Marjan Iravani; Alan Ashworth; Augusto Silva
Journal:  EMBO Rep       Date:  2006-02       Impact factor: 8.807

View more
  8 in total

1.  Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.

Authors:  Annemie A Van Linden; Dmitry Baturin; James B Ford; Susan P Fosmire; Lori Gardner; Christopher Korch; Philip Reigan; Christopher C Porter
Journal:  Mol Cancer Ther       Date:  2013-10-11       Impact factor: 6.261

2.  Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX.

Authors:  D K Walters; X Wu; R C Tschumper; B K Arendt; P M Huddleston; K J Henderson; A Dispenzieri; D F Jelinek
Journal:  Leukemia       Date:  2011-05-13       Impact factor: 11.528

3.  Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence.

Authors:  Agustin Chicas; Xiaowo Wang; Chaolin Zhang; Mila McCurrach; Zhen Zhao; Ozlem Mert; Ross A Dickins; Masashi Narita; Michael Zhang; Scott W Lowe
Journal:  Cancer Cell       Date:  2010-04-13       Impact factor: 31.743

4.  Could stress granules be involved in age-related diseases?

Authors:  Imed-Eddine Gallouzi
Journal:  Aging (Albany NY)       Date:  2009-09-21       Impact factor: 5.682

Review 5.  Targeting prostate cancer based on signal transduction and cell cycle pathways.

Authors:  John T Lee; Brian D Lehmann; David M Terrian; William H Chappell; Franca Stivala; Massimo Libra; Alberto M Martelli; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

6.  Role of the mammalian SWI/SNF chromatin remodeling complex in the cellular response to UV damage.

Authors:  Feng Gong; Deirdre Fahy; Hong Liu; Weidong Wang; Michael J Smerdon
Journal:  Cell Cycle       Date:  2008-01-18       Impact factor: 4.534

Review 7.  Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Ageing Res Rev       Date:  2008-12-09       Impact factor: 10.895

8.  Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.

Authors:  B Kubesova; S Pavlova; J Malcikova; J Kabathova; L Radova; N Tom; B Tichy; K Plevova; B Kantorova; K Fiedorova; M Slavikova; V Bystry; J Kissova; B Gisslinger; H Gisslinger; M Penka; J Mayer; R Kralovics; S Pospisilova; M Doubek
Journal:  Leukemia       Date:  2017-07-24       Impact factor: 11.528

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.